SOURCES SOUGHT
65 -- Sehorse XFe96 Analyzer
- Notice Date
- 6/19/2018
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Clinical Center/Office of Purchasing & Contracts, 6707 Democracy Blvd, Suite 106, MSC 5480, Bethesda, Maryland, 20892-5480
- ZIP Code
- 20892-5480
- Solicitation Number
- 18-012467
- Archive Date
- 6/29/2018
- Point of Contact
- Priscilla S. Abalos, Phone: 3015943879
- E-Mail Address
-
priscilla.abalos@nih.gov
(priscilla.abalos@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Solicitation # HHSN-NIH-CCOPC-SBSS-18-012467 This is a Small business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources:(2) whether there are small businesses, HUBZONE small businesses, service disabled veteran-owned small businesses or (8a) small businesses, veteran- owned small business, woman-owned small businesses or small disadvantaged businesses veteran owned small businesses; woman owned businesses, or small disadvantaged businesses and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable code should not submit a response to this notice. Background Information The Department of Transfusion Medicine (DTM) core Next Generation Sequencing (NGS) research lab is prioritized to be established with the following objectives- • Characterization of emerging cell therapy products to improve safety, purity, potency, stability and efficacy. • To advance the nascent development and science of red cell genotyping. • For development and molecular validation of red cell antigen expression algorithms to improve transfusion safety. In order to ensure further analysis of safety prior to clinical scale use of experimental therapies, the DTM NGS core facility is being developed to research newer technologies to be incorporated into patient care. As part of this goal, we intend to purchase the Seahorse XFe96 Analyzer to test cell potency prior to clinical use. 1. Explanation for how the agency intends to use the product or service in terms of function to be performed; and As part of core cellular therapy manufacturing services, the DTM/CPS also offers core research support, including new research technologies to measure cellular safety, purity, potency and consistency. Traditional assays which are based on flow cytometry only provide superficial information about cell quality prior to infusion. Hence improved methods are needed to perform additional analysis prior to using these expensive experimental therapies in humans. The agilent Seahorse XFe96 Analyzers measure OCR and ECAR of live cells in a 96-well plate format. OCR and ECAR rates are key indicators of mitochondrial respiration and glycolysis and these measurements provide a systems-level view of cellular metabolic function in cultured cells and ex-vivo samples. 2. Performance requirement or essential physical characteristics. In order to operate at optimal levels and incorporate novel research technologies for clinical use, the following attributes of the Seahorse analyzer are critical to establish a new potency assay. Real-time Results, Live-Cell Responses, Flexible Assay Design for large numbers of cell therapy product screening, High Sensitivity, Compatibility, Mitochondrial function measurement, Metabolic phenotype measurement within a few hours, Glycolytic rate measurement, Quick determination of dependency of cellular energy production on mitochondrial substrates, 3D sample analysis- such as spheroids and islets, User friendly assay protocol development and analysis. Delivery Schedule These reagents /disposables will be shipped overnight delivery Monday Through Thursday to: These supplies will be shipped for delivery Monday through Thursday to: NIH/CC/DTM/ 10 Center Drive Bldg. 10/ Rm. 3C720 Bethesda, MD 20892-1288 Attention: Thai Truong or Peta Chin Shipments will use government carrier at the expense of the government unless otherwise arranged. The contractor shall bear the cost of replacement for reagents and disposables found to be damaged or defective upon receipt by NIH or for incorrect or incomplete shipments. Government Responsibilities The Cell Processing Section shall use the reagents and disposables in accordance with manufacturer's package inserts and approved IND/IDE uses if applicable. The NIH CC Cell Processing Section shall inspect shipments upon receipt and report any damage, defects or errors in shipment to the contractor. Capability Statement is to include: Information regarding respondents; (a), including their availability, experience and informal and other training; (b) current in-house capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts; references, and other related information: Respondents, DUNS number, organization name, address, point of contract, and size and type of business (e.g.8(a), HUBZone, etc) pursuant to the applicable NAICS code; Respondents; technical and administrative points of contract including names, titles addresses, telephone and fax numbers and email addresses; Respondents must respond to this notice by June 26, 2018 12:00 pm Est DISCLAIMER AND IMPORTANT NOTICES: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After review of the responses received, a pre-solicitation synopsis and solicitation maybe published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a future solicitation. Primary Point of Contact Priscilla Abalos Contract Specialist Phone Number 301/594/5918
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/CCOPC/18-012467/listing.html)
- Place of Performance
- Address: National Institute of Health, 9000 Rockville Pike, Bldg10-3C-720, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04959897-W 20180621/180619230638-1af1602ece8bbe4f5426725bdb232d31 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |